In WM patients with mild anemia as the main criterion for initiating therapy who have IgM levels less than 3 gm/dl, single-agent rituximab may be a reasonable option for initial therapy.8, 17 However, it will take many months for a decrease in IgM levels to occur with rituximab alone. This evidence concerns the gene CD40LG and anemia.